Predictors of loss due to pharmaceutical fraud: evidence from the U.S.

Abstract

Background Globally and in the U.S. in particular, pharmaceutical fraud account for a large number out of all crimes in health care, which result into severe costs to the society. The Academy of Managed Care Pharmacists (Fraud, waste, and abuse in prescription drug benefits. 2019. Posted May 20. https://www.amcp.org/policy-advocacy/policy-advocacy-focus-areas/where-we-stand-position-statements/fraud-waste-and-abuse-prescription-drug-benefits.) estimate that pharmacy fraud is 1% of costs, therefore estimating that pharmacy fraud costs at $3.5 billion, given that pharmacy costs are $358 billion (Statista. Prescription drug expenditure in the United States from 1960 to 2020. 2021. https://www.statista.com/statistics/184914/prescription-drug-expenditures-in-the-us-since-1960/). Aim This exploratory study aims to demonstrate a fraudster’s profile as well as to estimate average consequences in terms of costs and identify the loss predictors’ hierarchy in the pharmaceutical industry in the U.S. Materials and methods Data from the Corporate Prosecution Registry and mixed-effects models are utilized for this purpose. The dataset covers years 2001–2020 and 75 cases, falling into one of the following broad sub-categories: misbranding, counterfeit, off-label use of drugs/deceptive marketing; violation of the Food, Drug and Cosmetic Act. Results The main factors positively associated with loss due to pharmaceutical fraud are: (i) duration of , and (ii) the scheme and scheme being executed at a U.S. public company. Surprisingly, presence of collusion negatively and significantly effects the cost. Potential factors include: (a) principal perpetrator being a white American and/or male, and (b) number of employees at individual and organizational level respectively. Conclusion This study empirically justifies considering loss, due to pharmaceutical fraud, from a multi-level perspective. Identified profiles of a typical fraudster helped to elaborate on specific practical recommendations aimed at pharmaceutical fraud prevention in the U.S.

Characteristics of Top-Searched Individuals in Japan’s Yen for Docs Conflicts of Interest Database During the COVID-19 Pandemic

“…The results also emphasize the need for more stringent regulations regarding the disclosure of FCOI in media and social networking services [36]. Considering the potential subconscious influence of FCOI on medical professionals' decisions, there is a call for transparency in financial relationships, significantly when such influence can shape public policies and opinions [37,38].…”

Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model

“…Whilst, people with insurance are expected to spend less on medicine, health insurance in Iran does not significantly reduce the burden. Weaknesses in the insurance support system can lead to OCT medicine supply and self-medication resulting in physical complications [ 50 ]. In general, treatment goals selection, patient education, generic medicines utilization and female heads empowerment are among the basic measures to reduce pharmaceutical expenditure [ 51 ].…”

How do moral hazard behaviors lead to the waste of medical insurance funds? An empirical study from China

“…Designated private hospitals and designated primary medical institutions were the main agencies generating insurance fraud. Some studies reported on similar types of health care fraud in private hospitals in other countries and highlight the risks and management costs that insurance fraud poses to private hospitals (10,(60)(61)(62). But in China, medical insurance funds are usually managed by government departments.…”

“…Global Health Care Anti-Fraud Network estimated that $260 billion, ~6% of global health care spending is lost due to fraud each year ( 8 ). The United States accounts for 3–10% of its health care expenditures each year caused by fraud claims and medical abuse, costing between $100 and $300 billion ( 9 , 10 ). The NHS Fraud Authority (NHS CFA) predicted that in the UK the NHS costs around £1.27 billion due to moral hazards such as fraud annually ( 11 ).…”